Quick Answer
BIO-TECHNE Corp reported Total Revenue of $1.22 billion for the year ending 2025.
- BIO-TECHNE Corp showed an increase of +5.2% in Total Revenue from 2024 to 2025.
- This data is from BIO-TECHNE Corp's annual report (Form 10-K), filed with the SEC on August 22, 2025.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2017: $144.61 million | Q4 2017: $154.15 million | Q1 2018: $163.97 million | Q3 2018: $162.97 million | Q4 2018: $174.51 million | Q1 2019: $184.86 million | Q3 2019: $183.24 million | Q4 2019: $184.93 million | Q1 2020: $194.68 million | Q3 2020: $204.20 million | Q4 2020: $224.25 million | Q1 2021: $243.55 million | Q3 2021: $257.72 million | Q4 2021: $269.28 million | Q1 2022: $290.38 million | Q3 2022: $269.66 million | Q4 2022: $271.58 million | Q1 2023: $294.15 million | Q3 2023: $276.94 million | Q4 2023: $272.60 million | Q1 2024: $303.43 million | Q3 2024: $289.46 million | Q4 2024: $297.03 million | Q1 2025: $316.18 million | Q3 2025: $286.56 million | Q4 2025: $295.88 million.
- Over the full 9 years of available data (2017 to 2025), BIO-TECHNE Corp's Total Revenue has grown by 116.6%.
- Historical annual values: Fiscal year 2025: $1.22 billion | Fiscal year 2024: $1.16 billion | Fiscal year 2023: $1.14 billion | Fiscal year 2022: $1.11 billion | Fiscal year 2021: $931.03 million | Fiscal year 2020: $738.69 million | Fiscal year 2019: $714.01 million | Fiscal year 2018: $642.99 million | Fiscal year 2017: $563.00 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: